[Value of the Coombs test in ABO incompatibility]

Area of Science:

• Neonatal Medicine
• Immunology
• Pediatrics

Context:

• ABO hemolytic disease of the newborn (HDN) poses significant clinical challenges.
• ABO incompatibility affects a notable percentage of pregnancies.
• Serological markers are crucial for predicting HDN severity.

Purpose:

• To investigate the serological aspects and clinical significance of ABO hemolytic disease of the newborn.
• To evaluate the utility of the direct antiglobulin test (DAT) in identifying at-risk infants.
• To establish guidelines for testing infants born to group O mothers.

Summary:

• A study of ABO hemolytic disease of the newborn found 21% of pregnancies were ABO incompatible.
• The direct antiglobulin test (DAT) was positive in 11.3% of these infants, with elution confirming antibody presence.
• High maternal anti-A or anti-B antibody titers (>1/128) were observed in 84% of cases. Infants with a positive DAT were exclusively born to group O mothers and did not experience prematurity.
• Jaundice requiring phototherapy occurred in 26% of DAT-positive infants, with one needing exchange transfusion.
• The DAT proved valuable in detecting infants susceptible to severe jaundice, supporting its use in neonates from group O mothers.

Impact:

• The direct antiglobulin test is a highly useful tool for identifying newborns at risk of severe jaundice.
• Routine DAT testing for infants born to group O mothers is recommended to facilitate timely intervention.
• Early detection and management of ABO hemolytic disease can prevent severe complications like exchange transfusion and reduce neonatal morbidity.